セミナーのお知らせ

A Flexible VLP Platform To Elicit Protective Responses For a Range of Targets

Dr. David Whitacre
Senior Vice President
VLP Biotech, Inc.,
San Diego, California



Date: January 6th Monday
Time: 3pm to 4 pm
Location: Biken Hall, 1st Floor, Main building,
Research Institute for Microbial Diseases

Traditional vaccines have been based on live-attenuated or killed pathogens and newer vaccines have targeted critical pathogen subunits. Further research has identified specific peptide targets that enable neutralizing a virus or bacterial toxin, sequestering an allergen, blocking an undesired signaling event or even stopping parasitic infection when antibodies bind the correct sequence. The concept of epitope-focused vaccines is not new, but peptides alone are poorly immunogenic and require a carrier to elicit potent antibody responses. We have developed a fully-recombinant virus-like particle (VLP) carrier that elicits potent antibody responses to precise peptidic targets by presentation in a matrix array on a highly-immunogenic particle. Our VLP is fully compatible with microbial expression, is self-assembling and highly stable, enabling a low cost-of-goods compatible with vaccines intended for worldwide use. We have proof-of-concept for a variety of pathogens and advanced preclinical programs are for a malaria vaccine to block sporozoite liver infection; an immune therapeutic for chronic hepatitis B infection; and a lyophilizable vaccine for anthrax.

【参考文献】

Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR. "Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance" *Human Vaccines & Immunotherapeutics* 2020, in press

Whitacre DC, Espinosa DA, Peters CJ, Jones JE, Tucker AE, Peterson DL, Zavala FP, Milich DR. "*P. falciparum* and *P. vivax* Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections" *PLoS One* 2015, 10(5): e0124856. doi:10.1371/journal.pone.0124856

Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR. "Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge" *Journal of Clinical Investigations* 2015, 125(4):1637–1647. doi:10.1172/JCI78450.

連絡先: マラリアワクチン開発寄附研究部門　堀井俊宏
horii@biken.osaka-u.ac.jp
Tel: 06-6879-8280

※医学系研究科単位認定の対象となるセミナーです。